Ulcerative Colitis Market Research Report- Forecast to 2030

Ulcerative Colitis Market Trends and Size Analysis by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), by Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics) - Forecast to 2030

ID: MRFR/Pharma/1737-HCR | October, 2022 | Region : Global

Table of Contents

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

5.1 ULCERATIVE PROCTITIS

5.2 PROCTOSIGMOIDITIS

5.3 LEFT-SIDED COLITIS

5.4 PANCOLITIS OR UNIVERSAL COLITIS

5.5 FULMINANT COLITIS

6. GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

6.1 5-AMINOSALICYLATES

6.2 STEROIDS

6.3 PURINE ANALOG

6.4 IMMUNOMODULATORS

6.5 BIOLOGICS

7. GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

7.1 NORTH AMERICA

7.1.1 INTRODUCTION

7.2 EUROPE

72.1 INTRODUCTION

7.3 ASIA-PACIFIC

7.3.1 INTRODUCTION

7.4 MIDDLE EAST & AFRICA

7.4.1 INTRODUCTION

8. COMPETITIVE LANDSCAPE

8.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

8..1.1 STRATEGIC PARTNERSHIP

8..1.2 MERGER & ACQUISITION

9 COMPANY PROFILE

9.1 ABBVIE INC.

9.1.1 OVERVIEW

9.1.2 PRODUCT OVERVIEW

9.1.3 FINANCIALS

9.1.4 KEY DEVELOPMENTS

9.2 BAYER AG.

9.2.1 OVERVIEW

9.2.2 PRODUCT OVERVIEW

9.2.3 FINANCIALS

9.2.4 KEY DEVELOPMENTS

9.3 JOHNSON & JOHNSON SERVICES, INC.,

9.3.1 OVERVIEW

9.3.2 PRODUCT OVERVIEW

9.3.3 FINANCIALS

9.3.4 STRATEGY

9.3.5 KEY DEVELOPMENT

9.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.4.1 OVERVIEW

9.4.2 PRODUCT OVERVIEW

9.4.3 FINANCIALS

9.4.4 KEY DEVELOPMENTS

9.5 PFIZER INC.

9.5.1 OVERVIEW

9.5.2 PRODUCT OVERVIEW

9.5.3 FINANCIALS

9.5.4 KEY DEVELOPMENTS

9.6 OTHERS

List of Tables

TABLE 1 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ULCERATIVE COLITIS MARKET BY REGION 2013-2022 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

FIGURE 4 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

FIGURE 5 GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

FIGURE 6 GLOBAL ULCERATIVE COLITIS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)

Ulcerative Colitis Market

The ulcerative colitis market will witness a growth at a significant CAGR 5.2% with value of USD 10.2 Billion by 2030

Segmentation

by type Ulcerative Proctitis Proctosigmoiditis Left Sided Colitis Pancolitis Or Universal Colitis Fulminant Colitis
by Medication 5 Aminosalicylates Steroids Purine Analogs Immunomodulators Biologics

Key Players

  • Salix Pharmaceuticals
  • Abbott Laboratories
  • Mitsubishi Tanabe Pharma Corporation
  • Celgene Corporation
  • InDex Pharmaceuticals Holding AB
  • BioLineRx Ltd
  • Sanofi Aventis A/S
  • Merck & Co
  • Eli Lilly
  • Johnson & Johnson

Drivers

  • Growing prevalence of bowel disease
  • Increases the production of drugs
Speak to Analyst Request a Free Sample